Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 3Q

Plavix sales were up 7% to $1.7 billion, but Abilify sales were -7% to $608 million, resulting from changed rebate rates.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 3Q

3Q Revenues: $4.8 billion (flat)

3Q Earnings: $949 million (-2%)

YTD Revenues: $14.4 billion (+4%)

YTD Earnings: $2.6 billion (+1%)

Comments: Plavix sales were up 7% to $1.7 billion, but Abilify sales were -7% to $608 million, resulting from changed rebate rates. Baraclude sales were up 19% to $228 million. Sustiva sales were up 9% to $342 million and Reyataz rose 4% to $375 million. Sprycel sales were $144 million (+35%) and Orencia sales were $184 million (+14%). Avapro/Avalide sales were down 8% to $303 million and Erbitux sales dropped 11% to $159 million. U.S. health care reform had a 2% negative effect on sales in the quarter. R&D expenses were flat at $824 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters